A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

NCT06868212 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria (CSU)

Interventions

DRUG: Remibrutinib
DRUG: Remibrutinib matching placebo
DRUG: Dupilumab
DRUG: Placebo solution for injection

Sponsor

Novartis Pharmaceuticals